Humanwell Healthcare (Group) Co. Ltd. has patented compounds acting a type-2 angiotensin II receptor (AGTR2; AT2) antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.
Aposense Ltd. has prepared and tested peptide-drug conjugates comprising a cell-penetrating peptide covalently bound to the therapeutically affective amino acid sequence (SAPK1 [JNK] inhibitors) linked to sterol derivatives through a linker reported to be useful for the treatment of cancer.
Nippon Chemiphar Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of cough, pain, pruritus, substance abuse and dependence, and liver, respiratory, neurological and cardiovascular disorders.
Terns Inc. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and liver diseases.
Evotec International GmbH and Nosopharm SAS have jointly described odilorhabdin analogues reported to be useful for the treatment of multidrug-resistant bacterial infections.
A patent from Nanjing Mingde New Drug Research Co. Ltd. and Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. details the identification of salts of interleukin-1 receptor-associated kinase 4 (IRAK-4) degradation inducers reported to be useful for the treatment of diffuse large B-cell lymphoma.
Work at LG Chem Ltd. has led to the development of novel benzimidazolone derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors potentially useful for the treatment of cancer and fibrosis.
RSS